L. Ledinsky

Cardiac safety of pembrolizumab-based neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: real-world experience from a single centre

The KEYNOTE-522 study established a new standard of care for patients with high-risk early triple-negative breast cancer by introducing pembrolizumab in combination with neoadjuvant chemotherapy. Myocarditis is a known, although rare, immune-related adverse event associated with anti–PD-1 therapy, with a reported...